-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The pharmaceutical industry is an important industry related to the national economy and people's livelihood and national security, and is also an important part of the life and health industry
.
Since the beginning of this year, many pharmaceutical development plans have been proposed to promote the development of the pharmaceutical industry
.
Among them, the "14th Five-Year Plan for the Development of the Pharmaceutical Industry in Anhui Province" pointed out that by 2025, the pharmaceutical industry in Anhui Province will achieve an operating income of 150 billion yuan
.
During the "14th Five-Year Plan" period, Anhui will aim at the new trend of global pharmaceutical development, relying on the construction of a comprehensive national science center in Hefei, accelerate the construction of scientific and technological innovation and achievement transformation and application system, and transform more scientific and technological achievements into real productive forces on the spot
.
At the same time, strengthen cross-disciplinary, cross-field, and cross-industry cooperation to promote innovation at the source of life science and technology and innovation in the entire chain of precision medicine
.
The "Plan" also mentioned that during the "Thirteenth Five-Year Plan" period, Anhui adhered to the consistency evaluation of generic drugs as the starting point, and systematically improved the production technology and quality control level of generic drugs
.
The "Implementation Plan for Accelerating the High-quality Development of the Biomedical Industry in Fujian Province" recently issued by Fujian proposes that by 2025, the province's pharmaceutical industry revenue will reach 120 billion yuan, and a number of leading backbone enterprises, key innovative products, technology research and development and Public service platform and characteristic industrial clusters
.
It is reported that in order to better promote the high-quality development of the biopharmaceutical industry, Fujian continues to increase financial support for the biopharmaceutical industry.
From 2022 to 2025, it plans to arrange a provincial special fund of nearly 1 billion yuan to support the development of the biopharmaceutical industry, of which , the support of a single enterprise in clinical trials can be up to 100 million yuan a year in financial subsidies; at the same time, in order to focus on building a highland for the biopharmaceutical industry in Xiamen, the basic industrial application platforms such as CRO and CMO that have landed in Xiamen are also included in the provincial level.
Scope of financial support
.
The innovation of Heilongjiang Province proposes to build six modern bio-industrial systems with Longjiang characteristics: bio-medicine, bio-agriculture, bio-manufacturing, bio-energy, bio-environmental protection, and bio-medical engineering
.
It strives that by 2025, the operating income of the biopharmaceutical industry will reach 100 billion yuan, the quality and efficiency will continue to improve, the transformation and upgrading will continue to accelerate, and it will enter a new stage of high-quality development of the entire industry chain
.
In order to promote the leapfrog development of the bio-economy, Heilongjiang Province issued the "Several Policies and Measures for Supporting the High-quality Development of the Bio-economy in Heilongjiang Province"
.
For biopharmaceutical products that complete Phase I, Phase II, and Phase III clinical trials, a maximum reward of 10 million yuan will be given according to the category; a maximum reward of 10 million yuan will be given to enterprises that have obtained the registration certificate of biomedical products and are producing in Heilongjiang Province for the first time; The province's first entry into the national top 100 pharmaceutical industry enterprises or the annual main business income of more than 100 million yuan and the top 5 enterprises in the sub-industry will be rewarded with a maximum of 2 million yuan; Newly put into production projects such as the production of Chinese herbal pieces and formula granules, Chinese herbal medicine extraction, industrialization of classic recipes, and food health care will be given a maximum of 5 million yuan of financial support according to the scale of investment in fixed assets
.
Yunnan Province proposed in the "14th Five-Year Plan for the Innovation and Development of the Biopharmaceutical Industry in Yunnan Province" that in terms of industrial scale and growth rate, by 2025, the operating income of the biopharmaceutical industry will achieve the goal of "protecting four and competing for five", that is, to ensure that 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth rate of more than 10%.
Among them, the biopharmaceutical manufacturing industry has achieved operating income of more than 150 billion yuan, with an average annual growth rate of more than 20%; the added value of the biopharmaceutical industry has reached 120 billion yuan, with an average annual growth rate of more than 20%.
Increase by more than 10%; in terms of industrial innovation capability, by 2025, strive to break through more than 100 key core technologies, develop more than 70 new products with strong innovation and great market potential, and invest more than 3% of the R&D investment in industrial enterprises above designated size And the coverage rate of R&D institutions is more than 90%
.
In terms of cultivating industrial entities, by 2025, cultivate more than 1 enterprise (group) with an operating income of 50 billion yuan, more than 5 enterprises (group) with an operating income of over 10 billion yuan, and more than 5 enterprises (group) with an operating income of more than 5 billion yuan.
, more than 20 enterprises (groups) exceeding 1 billion yuan, and more than 70 enterprises exceeding 100 million yuan
.
A total of more than 100 enterprises with more than 100 million yuan have been cultivated
.
In addition, Shanghai proposed in the "14th Five-Year Plan for the Development of Shanghai's Biomedical Industry" that by 2025, the development level of Shanghai's biopharmaceutical industry will be significantly improved, and it will initially be built into a core carrier of world-class biopharmaceutical industry clusters.
The scale of the pharmaceutical industry exceeds 1 trillion yuan, of which the output value of the manufacturing industry reaches 240 billion yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Since the beginning of this year, many pharmaceutical development plans have been proposed to promote the development of the pharmaceutical industry
.
Among them, the "14th Five-Year Plan for the Development of the Pharmaceutical Industry in Anhui Province" pointed out that by 2025, the pharmaceutical industry in Anhui Province will achieve an operating income of 150 billion yuan
.
During the "14th Five-Year Plan" period, Anhui will aim at the new trend of global pharmaceutical development, relying on the construction of a comprehensive national science center in Hefei, accelerate the construction of scientific and technological innovation and achievement transformation and application system, and transform more scientific and technological achievements into real productive forces on the spot
.
At the same time, strengthen cross-disciplinary, cross-field, and cross-industry cooperation to promote innovation at the source of life science and technology and innovation in the entire chain of precision medicine
.
The "Plan" also mentioned that during the "Thirteenth Five-Year Plan" period, Anhui adhered to the consistency evaluation of generic drugs as the starting point, and systematically improved the production technology and quality control level of generic drugs
.
The "Implementation Plan for Accelerating the High-quality Development of the Biomedical Industry in Fujian Province" recently issued by Fujian proposes that by 2025, the province's pharmaceutical industry revenue will reach 120 billion yuan, and a number of leading backbone enterprises, key innovative products, technology research and development and Public service platform and characteristic industrial clusters
.
It is reported that in order to better promote the high-quality development of the biopharmaceutical industry, Fujian continues to increase financial support for the biopharmaceutical industry.
From 2022 to 2025, it plans to arrange a provincial special fund of nearly 1 billion yuan to support the development of the biopharmaceutical industry, of which , the support of a single enterprise in clinical trials can be up to 100 million yuan a year in financial subsidies; at the same time, in order to focus on building a highland for the biopharmaceutical industry in Xiamen, the basic industrial application platforms such as CRO and CMO that have landed in Xiamen are also included in the provincial level.
Scope of financial support
.
The innovation of Heilongjiang Province proposes to build six modern bio-industrial systems with Longjiang characteristics: bio-medicine, bio-agriculture, bio-manufacturing, bio-energy, bio-environmental protection, and bio-medical engineering
.
It strives that by 2025, the operating income of the biopharmaceutical industry will reach 100 billion yuan, the quality and efficiency will continue to improve, the transformation and upgrading will continue to accelerate, and it will enter a new stage of high-quality development of the entire industry chain
.
In order to promote the leapfrog development of the bio-economy, Heilongjiang Province issued the "Several Policies and Measures for Supporting the High-quality Development of the Bio-economy in Heilongjiang Province"
.
For biopharmaceutical products that complete Phase I, Phase II, and Phase III clinical trials, a maximum reward of 10 million yuan will be given according to the category; a maximum reward of 10 million yuan will be given to enterprises that have obtained the registration certificate of biomedical products and are producing in Heilongjiang Province for the first time; The province's first entry into the national top 100 pharmaceutical industry enterprises or the annual main business income of more than 100 million yuan and the top 5 enterprises in the sub-industry will be rewarded with a maximum of 2 million yuan; Newly put into production projects such as the production of Chinese herbal pieces and formula granules, Chinese herbal medicine extraction, industrialization of classic recipes, and food health care will be given a maximum of 5 million yuan of financial support according to the scale of investment in fixed assets
.
Yunnan Province proposed in the "14th Five-Year Plan for the Innovation and Development of the Biopharmaceutical Industry in Yunnan Province" that in terms of industrial scale and growth rate, by 2025, the operating income of the biopharmaceutical industry will achieve the goal of "protecting four and competing for five", that is, to ensure that 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth rate of more than 10%.
Among them, the biopharmaceutical manufacturing industry has achieved operating income of more than 150 billion yuan, with an average annual growth rate of more than 20%; the added value of the biopharmaceutical industry has reached 120 billion yuan, with an average annual growth rate of more than 20%.
Increase by more than 10%; in terms of industrial innovation capability, by 2025, strive to break through more than 100 key core technologies, develop more than 70 new products with strong innovation and great market potential, and invest more than 3% of the R&D investment in industrial enterprises above designated size And the coverage rate of R&D institutions is more than 90%
.
In terms of cultivating industrial entities, by 2025, cultivate more than 1 enterprise (group) with an operating income of 50 billion yuan, more than 5 enterprises (group) with an operating income of over 10 billion yuan, and more than 5 enterprises (group) with an operating income of more than 5 billion yuan.
, more than 20 enterprises (groups) exceeding 1 billion yuan, and more than 70 enterprises exceeding 100 million yuan
.
A total of more than 100 enterprises with more than 100 million yuan have been cultivated
.
In addition, Shanghai proposed in the "14th Five-Year Plan for the Development of Shanghai's Biomedical Industry" that by 2025, the development level of Shanghai's biopharmaceutical industry will be significantly improved, and it will initially be built into a core carrier of world-class biopharmaceutical industry clusters.
The scale of the pharmaceutical industry exceeds 1 trillion yuan, of which the output value of the manufacturing industry reaches 240 billion yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
